Cite

HARVARD Citation

    Irving, P. et al. (n.d.). OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. Journal of Crohn's and colitis. pp. S001-S002. [Online]. 
  
Back to record